Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TL 118

Drug Profile

TL 118

Alternative Names: Hamsa 1; TL-111; TL-112

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tiltan Pharma
  • Class Nonsteroidal anti-inflammatories; Sulfonamides
  • Mechanism of Action Alkylating agents; Angiogenesis inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-II for Pancreatic cancer (Metastatic disease, Adjuvant therapy) in Israel, Israel, USA (PO)
  • 06 Oct 2017 TL 118 is still at phase II development stage for Pancreatic cancer (Adjuvant therapy, Metastatic disease) in Israel and USA (PO,suspension) (Tiltan Pharma website, October 2017)
  • 06 Oct 2017 No recent reports on development identified - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in Israel (PO,suspension)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top